Medicinal Products

749. Deputy Charles Ward asked the Minister for Health further to Parliamentary Question No. 2415 of 9 June 2026, the reason this data was not provided; when this data will be provided; and the most common reasons recorded for claim adjustment in each year from 2020 to date (details supplied) [52892/26]

750. Deputy Colm Burke asked the Minister for Health her views on extending publicly funded access to continuous glucose monitoring to all women with type 2 diabetes during pregnancy; and if she will make a statement on the matter. [52893/26]

751. Deputy Colm Burke asked the Minister for Health the number of people with a clinical diagnosis of type 1 diabetes who are currently ineligible for publicly funded continuous glucose monitoring access; and if she will make a statement on the matter. [52894/26]

752. Deputy Colm Burke asked the Minister for Health if she will consider widening access to continuous glucose monitoring (CGM) for women with type 2 diabetes during pregnancy (details supplied); and if she will make a statement on the matter. [52895/26]

753. Deputy Colm Burke asked the Minister for Health if the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will encompass a consideration of ensuring that all patients with type one diabetes have access to CGM; and if she will make a statement on the matter. [52898/26]

754. Deputy Colm Burke asked the Minister for Health whether the ongoing review of the preferred continuous glucose monitoring (CGM) sensors evaluation will lead to a HTA of CGM sensors for patients with type 2 diabetes; and if she will make a statement on the matter. [52899/26]

755. Deputy Barry Heneghan asked the Minister for Health whether the reimbursement arrangements under the community drugs schemes will be reviewed to ensure that patients are not financially disadvantaged when unlicensed medicines must be supplied as a result of shortages of licensed products; and if she will make a statement on the matter. [52900/26]

756. Deputy Barry Heneghan asked the Minister for Health whether her Department has assessed the financial impact of medicine shortages on residents of private nursing homes supported under the fair deal scheme, particularly where unlicensed medicines attract additional costs that are not fully covered under existing reimbursement arrangements; and if she will make a statement on the matter. [5290…

757. Deputy Barry Heneghan asked the Minister for Health the measures that are being taken by her Department and the HSE to minimise the impact of shortages of essential medicines, including medicines used in the treatment of heart failure and cardiovascular disease, and to ensure continuity of treatment for patients; and if she will make a statement on the matter. [52902/26]

758. Deputy Barry Heneghan asked the Minister for Health whether guidance has been issued to the HSE and community pharmacies regarding the reimbursement of unlicensed medicines supplied in place of licensed medicines that are unavailable due to national shortages; and if she will make a statement on the matter. [52903/26]

759. Deputy Barry Heneghan asked the Minister for Health the number and name of medicines currently subject to national shortages for which pharmacies are routinely sourcing unlicensed alternatives, in tabular form; whether her Department has assessed the additional costs incurred by medical card patients as a consequence; and if she will make a statement on the matter. [52904/26]

777. Deputy Aisling Dempsey asked the Minister for Health the reason tirzepatide (Mounjaro) is authorised for the treatment of type 2 diabetes but not covered by the medical card, long-term illness scheme or drugs payment scheme. [52993/26]

784. Deputy Jennifer Whitmore asked the Minister for Health if she will consider bringing trial adenomyosis drugs under the drug payment scheme or offering compensation for women who avail of these trial drugs; and if she will make a statement on the matter. [53005/26]

851. Deputy Pádraig O'Sullivan asked the Minister for Health the number of patients availing of the GMS medicines optimisation support service since its commencement on 1 June 2026; the number of patients previously in receipt of phased dispensing who have transitioned to the new service; and if she will make a statement on the matter. [53324/26]

852. Deputy Pádraig O'Sullivan asked the Minister for Health the projected full-year cost of the GMS medicines optimisation support service, including the €0.35 fee payable per GMS item dispensed and the €32.50 monthly enhanced medicines optimisation support fee, as agreed under the Community Pharmacy Agreement 2025; the amount paid out under each fee to date in 2026; and if she will make a statem…

853. Deputy Pádraig O'Sullivan asked the Minister for Health if she will publish the PCRS-approved list of medicines that qualify a patient for the enhanced medicines optimisation support fee under the GMS medicines optimisation support service; the clinical criteria used to compile that list; whether the list will be kept under review; and if she will make a statement on the matter. [53326/26]

854. Deputy Pádraig O'Sullivan asked the Minister for Health the eligibility criteria applying to the GMS medicines optimisation support service for patients with cognitive or physical impairment, intellectual disability, or experiencing social exclusion including homelessness; the method by which eligibility is assessed and by whom; the appeal mechanism available where a patient is refused access…

855. Deputy Pádraig O'Sullivan asked the Minister for Health the rationale for treating monitored dosage systems, commonly known as blister packs, as a last-resort option under the GMS medicines optimisation support service which commenced on 1 June 2026; her response to concerns that patients in residential care settings will no longer receive blister packs free of charge; the assessment her Depa…

856. Deputy Pádraig O'Sullivan asked the Minister for Health whether patients in receipt of free phased dispensing or blister packs in August 2025 will retain that support indefinitely under the GMS medicines optimisation support service; the arrangements for new patients who would previously have qualified; and if she will make a statement on the matter. [53329/26]

857. Deputy Pádraig O'Sullivan asked the Minister for Health the number of community pharmacies onboarded to date to the national unused medicines return and disposal scheme provided for under the Community Pharmacy Agreement 2025; the target date for all pharmacies to be participating; and if she will make a statement on the matter. [53333/26]

858. Deputy Pádraig O'Sullivan asked the Minister for Health the reason Ireland did not operate a national collection system for unused medicines despite the obligation under Directive 2004/27/EC, in place since 2004; the steps taken to ensure the new scheme achieves full compliance with that Directive; and if she will make a statement on the matter. [53334/26]

859. Deputy Pádraig O'Sullivan asked the Minister for Health when the planned public awareness campaign on the return of unused medicines to pharmacies will launch; the budget allocated to that campaign; and if she will make a statement on the matter. [53335/26]

860. Deputy Pádraig O'Sullivan asked the Minister for Health whether the review of the national unused medicines return and disposal scheme scheduled after nine months of operation will be published; the metrics that will be used to evaluate the scheme, including tonnage of medicines collected and pharmacy participation rates; and if she will make a statement on the matter. [53336/26]

861. Deputy Pádraig O'Sullivan asked the Minister for Health the assessment her Department has made of the contribution of unused medicines in the home to accidental poisoning of children, self-harm and suicide risk; whether data on hospital presentations linked to accidental ingestion of medicines by children will be used to evaluate the impact of the national unused medicines return scheme; and …

228. Deputy Ann Graves asked the Minister for Health if she is aware of the use of sativex (nabiximols), a pharmaceutical-grade spray, or any other standardised cannabinoid extracts licensed and available to assist those withdrawing from cannabis use; and her views on the dual diagnosis services that are available for those experiencing cannabis addiction and mental health issues. [52110/26]